Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | OGA | O60502 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23744105 | 0.84 | HTR3A (0.57) | HTR3AHRH4ROCK2PDE10AHCRTR1 | |
| SCHEMBL30345684 | 0.84 | HTR3A (0.57) | HTR3AHRH4ROCK2PDE10AHCRTR1 | |
| SCHEMBL14258880 | 0.80 | TSHR (0.47) | HTR3AHRH4ROCK2ROCK1HDAC1 | |
| SCHEMBL15543239 | 0.80 | KDM4E (0.57) | HTR3AHRH4HDAC1HTTPRKCQ | |
| SCHEMBL15589509 | 0.79 | HTR3A (0.51) | HTR3AHRH4HDAC1HTTPRKCQ | |
| SCHEMBL14305157 | 0.79 | HTR3A (0.51) | HTR3AHRH4HDAC1HTTPRKCQ | |
| SCHEMBL15589508 | 0.79 | HTR3A (0.51) | HTR3AHRH4HDAC1HTTPRKCQ | |
| SCHEMBL27471402 | 0.79 | HTR3A (0.50) | HTR3AHRH4ROCK2ROCK1PDE10A | |
| SCHEMBL4726050 | 0.78 | TSHR (0.46) | HTR3AHRH4ROCK2ROCK1HDAC1 | |
| SCHEMBL4725671 | 0.78 | TSHR (0.46) | HTR3AHRH4ROCK2ROCK1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3252045-B1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | ABBVIE INC (US) | 2019-09-04 | — | — | EP | disclosed |
| US-10112911-B2 | Substituted cyanoguanidines as oral anti-virals | ABBVIE INC. (US) | 2018-10-30 | — | — | US | disclosed |
| EP-2867221-B1 | CYANOGUANIDINES AND THEIR SUE AS ANTIVIRAL AGENTS. | ABBVIE INC (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-2867221-B1 | CYANOGUANIDINES AND THEIR SUE AS ANTIVIRAL AGENTS. | ABBVIE INC (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-3252045-A1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | AbbVie Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-3252045-A1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | AbbVie Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20150322045-A1 | CYANOGUANIDINES AND USES THEREOF | ABBVIE INC. | 2015-11-12 | — | — | US | disclosed |
| US-20150322045-A1 | CYANOGUANIDINES AND USES THEREOF | ABBVIE INC. | 2015-11-12 | — | — | US | disclosed |
| US-20150322045-A1 | CYANOGUANIDINES AND USES THEREOF | ABBVIE INC. | 2015-11-12 | — | — | US | disclosed |
| WO-2014005129-A1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | ABBVIE INC. (US) | 2014-01-03 | — | — | WO | disclosed |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| WO-2008005368-A2 | PIPERAZINES AS P2X7 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322045-A1 | CYANOGUANIDINES AND USES THEREOF | GMPS, RNGTT, RNMT | HTR3A 3352/4885HRH4 3735/4885ROCK2 1691/4885 |
| US-10112911-B2 | Substituted cyanoguanidines as oral anti-virals | RNGTT, GMPS, RNMT | HTR3A 3831/4885HRH4 2949/4885ROCK2 3179/4885 |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | P2RX7, P2RX1, P2RX2 | HTR3A 180/4885HRH4 817/4885ROCK2 4222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.